A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

被引：0
|
作者：
Advani, Anjali [1 ]
Copelan, Edward A. [1 ]
Sobecks, Ronald [1 ]
Sekeres, Mikkael A. [1 ]
Bates, Jennifer [1 ]
Rush, Mary Lynn [1 ]
Tripp, Barbara [1 ]
Noon, Elysa [2 ]
Howard, Matthew
Jin, Tao
Hsi, Eric
Kalaycio, Matt [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：351 / 352
页数：2
相关论文
共 50 条
  • [1] A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)
    Advani, Anjali S.
    Sobecks, Ronald
    Sekeres, Mikkael A.
    Copelan, Ed
    Bates, Jennifer
    Tripp, Barbara
    Salvado, August
    Kalaycio, Matt
    BLOOD, 2007, 110 (11) : 276A - 276A
  • [2] A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
    Advani, Anjali S.
    Tiu, Ramon
    Saunthararajah, Yogen
    Maciejewski, Jaroslaw
    Copelan, Edward A.
    Sobecks, Ronald
    Sekeres, Mikkael A.
    Bates, Jennifer
    Rush, Mary Lynn
    Tripp, Barbara
    Salvado, August
    Noon, Elysa
    Howard, Matthew
    Jin, Tao
    Hsi, Eric
    Egorin, Merrill J.
    Lim, Kathleen
    Cotta, Claudiu V.
    Price, Courtney
    Kalaycio, Matt
    LEUKEMIA RESEARCH, 2010, 34 (12) : 1622 - 1626
  • [3] Phase II study of imatinib in c-kit plus relapsed/refractory AML.
    Akhtar, A
    Seiter, K
    Liu, DL
    Qureshi, A
    BLOOD, 2003, 102 (11) : 871A - 871A
  • [4] A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)
    Advani, Anjali
    Cooper, Brenda
    Sowunmi, Olumuyiwa
    Elson, Paul
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu
    Sekeres, Mikkael A.
    Kalaycio, Matt
    Sobecks, Ronald
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Davis, Randall
    Bailey, Laura
    Foster, Bethany
    Rush, Mary Lynn
    Adams, Donna
    Tse, William
    BLOOD, 2012, 120 (21)
  • [5] A phase II pilot study of Gleevec/Glivec (imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML).
    Fischer, T
    Beck, J
    Duyster, J
    Peschel, C
    Müller-Navia, J
    Jäger, E
    Knuth, A
    Gschaidmeier, H
    Huber, C
    BLOOD, 2002, 100 (11) : 561A - 561A
  • [6] Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Tse, William
    Jia, Xuefei
    Elson, Paul
    Cooper, Brenda
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati V.
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu V.
    Kalaycio, Matt
    Sobecks, Ronald M.
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Fensterl, Jaime
    Bailey, Laura
    Carew, Jennifer S.
    Foster, Bethany
    Rush, Mary Lynn
    Adams, Donna
    Griffiths, Elizabeth A.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [7] A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
    Chevallier, Patrice
    Hunault-Berger, Mathilde
    Larosa, Fabrice
    Dauriac, Charles
    Garand, Richard
    Harousseau, Jean-Luc
    LEUKEMIA RESEARCH, 2009, 33 (08) : 1124 - 1126
  • [8] Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma
    Sugiura, Hideshi
    Fujiwara, Yasuhiro
    Ando, Masashi
    Kawai, Akira
    Ogose, Akira
    Ozaki, Toshifumi
    Yokoyama, Ryohei
    Hiruma, Toru
    Ishii, Takeshi
    Morioka, Hideo
    Mugishima, Hideo
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2010, 15 (05) : 654 - 660
  • [9] The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R
    Gross, DJ
    Munter, G
    Bitan, M
    Siegal, T
    Gabizon, A
    Weitzen, R
    Merimsky, O
    Ackerstein, A
    Salmon, A
    Sella, A
    Slavin, S
    ENDOCRINE-RELATED CANCER, 2006, 13 (02) : 535 - 540
  • [10] The role of imatinib mesylate (Glivec®) forTreatment of patients with malignant endocrine tumors positive for c-Kit or PDGF-R
    Gross, DJ
    Munter, G
    Bitan, M
    Siegal, T
    Gabizon, A
    Weitzen, R
    Merimsky, O
    Ackerstein, A
    Peretz, T
    Sella, A
    Slavin, S
    NEUROENDOCRINOLOGY, 2006, 83 (01) : 34 - 35
12345